KKL 顾客使用本产品发表的 0 篇科研文献

YM17E is an inhibitor of acyl CoA:cholesterol acyltransferase (ACAT), with IC₅₀ of 44 nM in rabbit liver microsomes in vitro.

YM17E is as potent in inhibiting ACAT activity in the liver as in the intestine, with IC₅₀ values of 45 and 34 nM, respectively.

YM17E (3, 10 and 30 mg/kg per day, p.o.) decreases total cholesterol, cholesteryl ester and non-HDL cholesterol in a dose-dependent manner. Total cholesterol and cholesteryl ester levels in liver do not decrease significantly after intravenous administration of YM17E, but do decrease significantly and in a dose-dependent manner after oral administration. YM17E (3, 5, 10 mg/kg, i.v.) significantly inhibits hepatic ACAT activities in a dose-dependent manner. YM17E produces a significant increase in I-LDL clearance in atherogenic diet-fed rats after both oral and intravenous administration. YM17E inhibits production of [C]cholesteryloleate from [C]oleoyl CoA in a dose-dependent manner in both liver and intestinal microsomes used as enzyme sources.

Room temperature in continental US; may vary elsewhere.